Can a pill target Hard-to-Treat ovarian cancers?
NCT ID NCT05226507
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental oral drug called NXP800 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find the safest dose and schedule, and then to see if the drug shows promise in specific ovarian cancers that carry an ARID1A gene mutation. The goal is to understand the drug's safety and whether it can shrink or control these tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NXP800, an oral small molecule drug
- What this could lead to
- If successful, NXP800 could become a new treatment option for advanced solid tumors, especially ovarian cancers with ARID1A mutations.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drug may not prove effective or safe. Side effects and dose-limiting toxicities are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Addenbrookes Hospital
Cambridge, CB2 0QQ, United Kingdom
-
Florida Cancer Specialists Research East
West Palm Beach, Florida, 33401, United States
-
Florida Cancer Specialists Research North
St. Petersburg, Florida, 33705, United States
-
Florida Cancer Specialists South
Fort Myers, Florida, 33901, United States
-
Honor Health
Phoenix, Arizona, 85016, United States
-
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma, 74146, United States
-
Oncology Associates of Oregon
Eugene, Oregon, 97401, United States
-
Royal Marsden Hospital
Sutton, Sutton Surrey, SM2 5PT, United Kingdom
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
Sidney Kimmel Cancer Center, Asplundh Cancer Pavilion
Willow Grove, Pennsylvania, 19090, United States
-
Texas Oncology
Fort Worth, Texas, 76104, United States
-
The Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UC San Diego Health - Moores Cancer Center
La Jolla, California, 92093, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Women's Cancer Care Associates
Albany, New York, 12208, United States
-
Yale Gynecologic Oncology
New Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?